Kimberly-Clark Corporation (NASDAQ:KMB) rattled its shareholders when it earlier announced its acquisition of consumer goods giant Kenvue Inc (NYSE:KVUE). Ordinarily, such an acquisition might make sense due to the implied expansion of the acquiring entity's product portfolio. However, Kenvue has been ground zero for a controversy involving the flagship over-the-counter medication Tylenol.
Looking at the terms of the deal, the cash and stock transaction values Kenvue at an enterprise value of about $48.7 billion, based on the closing price of KMB stock this past Halloween. Further, the total deal value reflects an acquisition multiple of about 14.3 times Kenvue's last twelve months (LTM) adjusted EBITDA. Fundamentally, the combined enterprise aims to build on a stronger commercial platform to better meet evolving consumer needs.
